Document:

Exhibit

Exhibit 4.5

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of February 25, 2020, Radius Health, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.

Description of Common Stock 
General 
Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock and provisions of our restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our restated certificate of incorporation and amended and restated bylaws. 
Common Stock 
Each holder of our common stock is entitled to one vote for each share held on all matters submitted to a vote of stockholders. Our stockholders do not have cumulative voting rights. Accordingly, the holders of a majority of the voting shares are able to elect all of the directors then up for election, except that in the case of a contested election, which occurs where the number of director nominees exceeds the number of directors to be elected, the election will be determined by a plurality of the votes cast. Any incumbent director who is not re-elected must tender his or her resignation to our board of directors. Our nominating and corporate governance committee will make a recommendation to our board of directors as to whether to accept or reject the resignation, or whether other action should be taken. Our board of directors will act on the recommendation and publicly disclose its decision within 90 days following certification of the voting results. An incumbent director who tenders his or her resignation may not participate in such decisions of our nominating and corporate governance committee or our board of directors. 
Subject to preferential dividend rights of any series of preferred stock that we may designate and issue in the future, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. In the event of our liquidation or dissolution, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. 
Anti-Takeover Provisions 
Our restated certificate of incorporation provides for our board of directors to be divided into three classes, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors then up for election, except that in the case of a contested election, which occurs where the number of director nominees exceeds the number of directors to be elected, the election will be determined by a plurality of the votes cast. Our restated certificate of incorporation and amended and restated bylaws provide that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing, and that only our board of directors, chairman of the board, chief executive officer or president (in the absence of a chief executive officer) may call a special meeting of stockholders. 

  
Our restated certificate of incorporation requires a two-thirds stockholder vote for the amendment, repeal or modification of certain provisions of our restated certificate of incorporation and amended and restated bylaws relating to the classification of our board of directors, the requirement that stockholder actions be effected at a duly called meeting, and the designated parties entitled to call a special meeting of the stockholders. The combination of the classification of our board of directors, the lack of cumulative voting and the two-thirds stockholder voting requirements make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. 
Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty, or other wrongdoing, by any of our directors, officers, employees or agents to us or our stockholders, creditors or other of constituents; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. 
These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. These provisions may also have the effect of preventing changes in our management. 
Section 203 of the Delaware General Corporation Law 
We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: 
 
	
				
	 
	•
	 
	if, before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder;

 

	
				
	 
	•
	 
	if, upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 
	
				
	 
	•
	 
	if, on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.

  
In general, Section 203 defines business combination to include the following: 
 
	
				
	 
	•
	 
	any merger or consolidation involving the corporation and the interested stockholder;

 
	
				
	 
	•
	 
	any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

 
	
				
	 
	•
	 
	subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 
	
				
	 
	•
	 
	any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

 
	
				
	 
	•
	 
	the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. 
Transfer Agent and Registrar 
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. 
Listing 
Our common stock is listed on the Nasdaq Global Market under the symbol “RDUS.”Exhibit

Exhibit 10.20(a)

Certain information identified in this document, marked by “[*]”, has been excluded pursuant to Regulation S-K, Item 601(b)(10) because it is not material and would likely cause competitive harm to the registrant if publicly disclosed.

AMENDMENT #1 TO 
COMMERCIAL SUPPLY AGREEMENT

This Amendment #1 to the Commercial Supply Agreement is made and entered into the 1st  day of December 2019 (the “Amendment #1 Effective Date”) by and between Vetter Pharma International GmbH, a company duly organized and existing under the laws of Germany, having its principal place of business at Eywiesenstraβe 5, 88212 Ravensburg, Germany (“Vetter”) and Radius Health, Inc., a Delaware corporation having its principal office at 950 Winter Street, Waltham, Massachusetts, 02139, USA (“Radius)”.  The Parties agree as follows:

WHEREAS, Vetter and Radius previously entered into that certain Commercial Supply Agreement effective January 1, 2016, as amended, (the “Agreement”); and

WHEREAS, the Parties desire to amend the Agreement to reflect the purchase of back-ups of certain critical equipment set forth herein, on the terms and conditions in this Amendment #1.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

ARTICLE 1: AMENDMENTS

		
	1.
	Appendix A, “Radius Equipment,” is hereby amended by adding the following equipment set forth below:

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	•
	[*] ([*] Euro)

		
	2.
	Upon execution of this Amendment #1 and receipt of a purchase order from Radius, Vetter shall order and purchase the above-listed equipment. Radius shall reimburse Vetter within thirty (30) calendar days of the date of Vetter’s respective invoice.  For the avoidance of doubt, in the absence of any provision in this Amendment #1, the “Prices and Payments” terms Article 8 of the Agreement shall apply. 

ARTICLE 2: MISCELLANEOUS

		
	1.
	Capitalized terms used but not defined in this Amendment #1 shall have the meanings given to such terms in the Agreement.

		
	2.
	In the event of any conflict between the provisions of this Amendment #1 and any of the provisions of the Agreement, the provisions of this Amendment #1 shall govern in all respects.

		
	3.
	Except as specifically modified herein, the terms and conditions of the Agreement including its appendices are hereby affirmed, confirmed and ratified and the Agreement, as amended, shall remain in full force and effect.  For the avoidance of doubt, anything which is not covered in this Amendment #1, shall be subject to the provisions of the Agreement.

(Page remainder left blank intentionally, immediately followed by the signatures page.)

2
    

IN WITNESS WHEREOF, the Parties have caused this Amendment #1 to be duly executed by their duly authorized representatives as of the Amendment #1 Effective Date.

Radius Health, Inc.  

Waltham, MA, United States of America, dated this 5th day of January, 2020

	
		
	(signed)
	/s/ Judson Taylor

	 
	 

	Name:
	Judson Taylor

	 
	 

	Title
	Executive Director, Supply Chain

Vetter Pharma International GmbH

Ravensburg, Germany, dated this 4th day of December, 2019

	
				
	(signed)
	/s/ Jeffrey C. Ellenburg
	(signed)
	/s/ Hermann Klein

	 
	 
	 
	 

	Name:
	Jeffrey C. Ellenburg
	Name:
	Hermann Klein

	 
	 
	 
	 

	Title
	Director, Key Account Management Europe
	Title:
	Key Account Manger

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]